{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:10:29Z","timestamp":1789017029749,"version":"build-2803163510"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Acute generalized pustular psoriasis (GPP) is a rare, distinct subtype of psoriasis characterized clinically by sterile pustules arising on an erythematous base. Pediatric GPP is associated with severe manifestations, high healthcare expenditures, and a great risk of mortality, severely affecting the quality of life of both children and their families. Secukinumab, a fully human monoclonal antibody that selectively targets IL-17A\u2014a pivotal cytokine in psoriasis pathogenesis that promotes keratinocyte proliferation and inflammatory responses\u2014has been approved for the treatment of moderate-to-severe plaque psoriasis in children aged 6\u201318 years. Here, we describe three pediatric patients with GPP who were successfully treated with secukinumab. To date, no secukinumab-related adverse effects have been observed among the three pediatric patients throughout their respective follow-up periods. Secukinumab may be an effective option for the treatment of GPP in children.<\/jats:p>","DOI":"10.3389\/fmed.2026.1867541","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:28:57Z","timestamp":1789014537000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Successful treatment of pediatric patients with acute generalized pustular psoriasis with secukinumab"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiqi","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Children\u2019s Hospital, Tianjin University\/Tianjin Children\u2019s Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Children\u2019s Hospital, Tianjin University\/Tianjin Children\u2019s Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Children\u2019s Hospital, Tianjin University\/Tianjin Children\u2019s Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Children\u2019s Hospital, Tianjin University\/Tianjin Children\u2019s Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinfeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Children\u2019s Hospital, Tianjin University\/Tianjin Children\u2019s Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40257-021-00655-y","article-title":"Pathophysiology of generalized pustular psoriasis","volume":"23","author":"Marrakchi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1468-3083.2007.02014.x","article-title":"Childhood psoriasis: a study of 277 patients from China","volume":"21","author":"Fan","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jaad.2022.03.050","article-title":"Treating generalized pustular psoriasis: the path forward","volume":"86","author":"Heymann","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1007\/s13555-025-01483-2","article-title":"A global assessment of patient experience and quality of life in generalized pustular psoriasis: results from interviews and online surveys","volume":"15","author":"Kole","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/1346-8138.17049","article-title":"Pediatric psoriasis: understanding pathological conditions and advances in treatment","volume":"51","author":"Morita","year":"2024","journal-title":"J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12920-023-01507-w","article-title":"Identification immune response genes in psoriasis after treatment with secukinumab","volume":"16","author":"Wang","year":"2023","journal-title":"BMC Med Genomics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40265-021-01476-3","article-title":"Secukinumab: a review in psoriatic arthritis","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40257-023-00779-3","article-title":"Acute generalized exanthematous pustulosis: clinical features, differential diagnosis, and management","volume":"24","author":"Parisi","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.jid.2017.12.024","article-title":"Unopposed IL-36 activity promotes clonal CD4+T-cell responses with IL-17A production in generalized pustular psoriasis","volume":"138","author":"Arakawa","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1111\/1346-8138.17471","article-title":"Asia-pacific consensus recommendations on the management of generalized pustular psoriasis","volume":"51","author":"Choon","year":"2024","journal-title":"J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1080\/09546634.2021.1899111","article-title":"Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series","volume":"33","author":"Albela","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2443121","DOI":"10.1080\/09546634.2024.2443121","article-title":"Long-term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study","volume":"36","author":"Xing","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1111\/1346-8138.70199","article-title":"Successful discontinuation of systemic corticosteroids with secukinumab in a pediatric case of generalized pustular psoriasis harboring an IL36RN mutation","volume":"53","author":"Mori","year":"2026","journal-title":"J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8199","DOI":"10.2147\/JIR.S485077","article-title":"Successful treatment of pediatric generalized pustular psoriasis (GPP) with spesolimab: 5 case reports and evaluations of circulating IL-36 levels","volume":"17","author":"Chen","year":"2024","journal-title":"J Inflamm Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/ijd.70079","article-title":"Refractory pediatric generalized pustular psoriasis successfully treated with spesolimab","volume":"65","author":"Peng","year":"2026","journal-title":"Int J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.2147\/CCID.S574980","article-title":"Immunological antagonism between psoriasis and atopic dermatitis: pathways, clinical implications, and therapeutic perspectives","volume":"18","author":"Qin","year":"2025","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"adv00077","DOI":"10.2340\/00015555-3435","article-title":"Cutaneous vasculitis with gut involvement during secukinumab treatment for psoriatic arthritis","volume":"100","author":"Chelli","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/ijd.ijd_871_22","article-title":"Biologics-induced immunophenotypic cross-switching in patients with psoriasis and atopic dermatitis","volume":"68","author":"Li","year":"2023","journal-title":"Indian J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/jdv.20739","article-title":"Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: a British Association of Dermatologists biologics and immunomodulators register cohort study","volume":"39","author":"Motedayen Aval","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1867541\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:29:01Z","timestamp":1789014541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1867541\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":22,"alternative-id":["10.3389\/fmed.2026.1867541"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1867541","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1867541"}}